Advancing the Development of Targeted, Scalable Cell Therapies Through Disruptive Ex Vivo & In Vivo Technologies, Automated Manufacturing & Strategic Partnerships to Safeguard the Commercial Success of the Industry
The cell therapy field is entering a more demanding phase, with focus shifting from early momentum to long-term commercial success. Attention is turning to novel innovations like in vivo therapies and automated manufacturing: two game-changing strategies that promise to cut costs, speed up development, and unlock commercial viability. With more than $6.6 billion invested in the last six months from the likes of AbbVie and Kite, investor confidence is returning, but with clear expectations. It’s critical to adapt to this next wave of innovation where standout clinical data and scalable platforms are non-negotiable.
The 11th CAR-TCR Summit was your must attend forum, bringing together the latest scientific innovation across therapeutic classes and indications to inform your business strategy and support long term commercial success. Renowned for its caliber of networking and unparalleled depth of content, this event had cutting-edge clinical data on ex vivo and in vivo advances, clinical trial strategies to support expanded patient access across indications, scalable and automated manufacturing processes to improve speed and costs, as well as commercial reflections to learn from those on the market.
Built for Depth, Not Dilution:
Attending Companies Included
What Defined The 2026 Meeting:
Unmatched Seniority & Unfiltered Perspectives:
With 40% C-suite executives, 55% VPs and directors, VC partners and academic KOLs, attendees gained direct access to the decision makers defining the trajectory of cell therapy, test ideas, refine your pipeline and ignite partnerships.
The Strategy & Innovation Day:
Attendees joined a curated group of peers for closed-door discussions, candid knowledge exchange and hyper-focused networking in an immersive deep dive bootcamp focused on a single critical topic. They explored next generation data and strategy across Cell Therapy Fundamentals, In Vivo, Automated Manufacturing and Regulations & Investment.
World’s Most Influential Cell Therapy Community:
With a highly specialized audience of CAR and TCR experts in attendance, this was your opportunity to network with the most prominent stakeholders, build on the lessons of those further ahead and validate your approach to advance your pipeline for 2027 and beyond.
Representation from 70% of the Top Cell Therapy Pharma Companies:
Attendees heard frontline learnings and acquisition strategies from Kite Pharma, Eli Lilly, Regeneron, Novartis, AstraZeneca, Bristol Myers Squibb and Johnson & Johnson across evolving clinical, manufacturing, and licensing developments.
Uniting Scientific Innovation, Manufacturing Scale & Business Strategy:
Attendees uncoverd the proven development playbook through expert-led deep dives, while connecting with pharma, VC and business development decision-makers to advance their pipeline towards clinical and commercial success.
Unmatched Technical Depth into Cell Therapy Advances:
Beyond access to unpublished preclinical and clinical data, attendees immersed themselves in in-depth technical case studies, understood how the industry’s thought leaders interpret findings and asked critical questions to extract the insights that directly affect their pipeline development.
A Conversation on Hope, Access & the Future of CAR-T
Ahead of the 11th CAR-TCR Summit, Pei Wang, Senior Vice President, Clinical Development & CMC at Eureka Therapeutics, and Brad Watts, CAR-T recipient and patient advocate with the Emily Whitehead Foundation, shared a powerful discussion on the life-changing impact of cell therapy. Together, they reflected on the patient journey, the importance of patient-centred innovation, and their hopes for expanding access and advancing the next generation of CAR-T therapies.
Explore the 2026 Event Guide
- Discover 75+ industry-leading speakers from across biotech, commercialized pharma, venture capital and academic KOLs
- Get a preview of all featured unpublished phase I and II clinical data presentation descriptions and the industry's latest breakthroughs
- Explore who you’ll be connecting with to map out your conversations across 14 hours of focused networking
2026 Partners
Lead Partner
Expertise Partners
Innovation Partners
Program Partners
Attending Companies Included
Explore Related Events
Explore the 2026 Agenda
Get a front row seat to the latest cell therapy breakthroughs across autoimmune disease, solid tumors and novel modalities through data-driven technical presentations, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of cell therapy deals.
Join Biopharma Experts
Be part of the hottest conversations in this tailor-made forum for senior executives across all stages of CAR and TCR drug development and make critical connections during our dedicated networking sessions and CAR-TCR Connect drinks reception.